

# Stanford

---



## David Iberri

Clinical Assistant Professor, Medicine - Hematology

### CLINICAL OFFICES

- **Stanford Cancer Center**

875 Blake Wilbur Dr

MC 6560

Stanford, CA 94305

**Tel** (650) 498-6000

**Fax** (650) 724-5203

### Bio

---

### BIO

Dr. Iberri is a medical oncologist and hematologist who specializes in the treatment of hematologic malignancies. His clinical practices runs the gamut of malignant and non-malignant hematologic disorders including acute and chronic leukemias, multiple myeloma and lymphomas, and bleeding and thrombotic disorders. He is actively involved in clinical trials evaluating novel agents in hematologic malignancies. His research interests are in the development and application of biomarkers to select patients most likely to benefit from therapy.

### CLINICAL FOCUS

- Lymphoma
- Chronic Lymphocytic Leukemia
- Multiple Myeloma
- Acute Myeloid Leukemia
- Chronic Myeloid Leukemia
- Polycythemia Vera
- Essential Thrombocythemia
- Myeloproliferative Disorders
- Iron Deficiency Anemia
- Venous Thromboembolism
- Aplastic Anemia
- Hematology

### ACADEMIC APPOINTMENTS

- Clinical Assistant Professor, Medicine - Hematology

### ADMINISTRATIVE APPOINTMENTS

- Member, Stanford Professional Practice Evaluation Committee, (2016- present)

### PROFESSIONAL EDUCATION

- Board Certification: Hematology, American Board of Internal Medicine (2016)
- Fellowship: Stanford University School of Medicine (2015) CA
- Board Certification: Internal Medicine, American Board of Internal Medicine (2013)
- Residency: Stanford University School of Medicine (2013) CA

- Internship: Stanford University School of Medicine (2011) CA
- Medical Education: University of Vermont College of Medicine (2010) VT

## Research & Scholarship

---

### CLINICAL TRIALS

- A Safety and Efficacy Study to Evaluate Luspatercept in Subjects With Myeloproliferative Neoplasm-associated Myelofibrosis Who Have Anemia With and Without Red Blood Cell-transfusion Dependence, Recruiting
- Venetoclax and Ibrutinib in Patients With Relapsed/Refractory CLL or SLL, Recruiting
- A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy, Not Recruiting
- Decitabine and Midostaurin in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia, Not Recruiting
- Elevate CLL TN: Study of Obinutuzumab + Chlorambucil, Acalabrutinib (ACP-196) + Obinutuzumab, and Acalabrutinib in Subjects With Previously Untreated CLL, Not Recruiting
- Lenalidomide and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Not Recruiting
- Midostaurin in Treating Older Patients With Mutated Acute Myeloid Leukemia Post-Transplant, Not Recruiting
- Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Subjects With High Risk CLL, Not Recruiting

## Teaching

---

### GRADUATE AND FELLOWSHIP PROGRAM AFFILIATIONS

- Hematology (Fellowship Program)
- Oncology (Fellowship Program)

## Publications

---

### PUBLICATIONS

- **Clinical and Laboratory Features of Autoimmune Hemolytic Anemia Associated with Immune Checkpoint Inhibitors.** *American journal of hematology*  
Leaf, R. K., Ferreri, C., Rangachari, D., Mier, J., Witteles, W., Anstas, G., Anagnostou, T., Zubiri, L., Piotrowska, Z., Oo, T. H., Iberri, D., Yarchoan, M., Salama, et al  
2019
- **Dynamic BH3 Profiling Predicts for Clinical Response to Lenalidomide Plus Chemotherapy in Relapsed Acute Myeloid Leukemia**  
Garcia, J. S., Bhatt, S., Fell, G., Blonquist, T. M., Taw, J., Iberri, D., Letai, A., Medeiros, B. C.  
AMER SOC HEMATOLOGY.2018
- **Postibrutinib outcomes in patients with mantle cell lymphoma** *BLOOD*  
Martin, P., Maddocks, K., Leonard, J. P., Ruan, J., Goy, A., Wagner-Johnston, N., Rule, S., Advani, R., Iberri, D., Phillips, T., Spurgeon, S., Kozin, E., Noto, et al  
2016; 127 (12): 1559-1563
- **Ibrutinib-associated rash: a single-centre experience of clinicopathological features and management.** *British journal of haematology*  
2016
- **Ibrutinib-Associated Rash: Single-Center Experience of Clinicopathologic Features and Management**  
Iberri, D. J., Kwong, B., Stevens, L., Coutre, S. E., Kim, J., Sabile, J., Advani, R. H.  
AMER SOC HEMATOLOGY.2015
- **Balancing Safety and Efficacy of Epidermal Growth Factor Receptor Inhibitors in Patients With Squamous Cell Carcinoma of the Head and Neck** *ONCOLOGIST*  
Iberri, D. J., Colevas, A. D.  
2015; 20 (12): 1393-1403
- **Hodgkin Lymphoma: the Changing Role of Radiation Therapy in Early-Stage Disease—the Role of Functional Imaging.** *Current treatment options in oncology*

Iberri, D. J., Hoppe, R. T., Advani, R. H.  
2015; 16 (9): 45-?

● **Building a Modern Journal Club: The Wiki Journal Club Experience.** *Journal of graduate medical education*

Plante, T. B., Iberri, D. J., Coderre, E. L.  
2015; 7 (3): 341-43

● **Clinical Evidence Summary Apps: Definition, Role, and Unknowns About a Novel Medical Content Delivery Genre.** *Journal of graduate medical education*

Plante, T. B., Kane, S. P., Iberri, D. J., Majure, D. T.  
2014; 6 (4): 791-?

● **Clinicopathologic Characteristics of HER2 FISH-ambiguous Breast Cancer at a Single Institution** *AMERICAN JOURNAL OF SURGICAL PATHOLOGY*

Clay, M. R., Iberri, D. J., Bangs, C. D., Cherry, A., Jensen, K. C.  
2013; 37 (1): 120-127

● **Wikipedia: A Key Tool for Global Public Health Promotion** *JOURNAL OF MEDICAL INTERNET RESEARCH*

Heilman, J. M., Kemmann, E., Bonert, M., Chatterjee, A., Ragar, B., Beards, G. M., Iberri, D. J., Harvey, M., Thomas, B., Stomp, W., Martone, M. F., Lodge, D. J., Vondracek, et al  
2011; 13 (1): 153-164